Françoise Rédiní

10.4k total citations · 2 hit papers
181 papers, 7.9k citations indexed

About

Françoise Rédiní is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Françoise Rédiní has authored 181 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Molecular Biology, 83 papers in Oncology and 49 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Françoise Rédiní's work include Bone health and treatments (51 papers), Sarcoma Diagnosis and Treatment (46 papers) and Bone Metabolism and Diseases (39 papers). Françoise Rédiní is often cited by papers focused on Bone health and treatments (51 papers), Sarcoma Diagnosis and Treatment (46 papers) and Bone Metabolism and Diseases (39 papers). Françoise Rédiní collaborates with scholars based in France, United States and Canada. Françoise Rédiní's co-authors include Dominique Heymann, Frédéric Blanchard, Franck Verrecchia, Sandrine Théoleyre, Yohann Wittrant, François Lamoureux, Benjamin Ory, Valérie Trichet, Kanji Mori and Marie‐Françoise Heymann and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Françoise Rédiní

176 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling

2004 518 citations Françoise Rédiní, Dominique Heymann et al. profile →
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem

2020 334 citations Franck Verrecchia, Vincent Crenn et al. Cells profile →

Peers

Countries citing papers authored by Françoise Rédiní

Since Specialization

Citations

This map shows the geographic impact of Françoise Rédiní's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Françoise Rédiní with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Françoise Rédiní more than expected).

Fields of papers citing papers by Françoise Rédiní

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Françoise Rédiní. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Françoise Rédiní. The network helps show where Françoise Rédiní may publish in the future.

Co-authorship network of co-authors of Françoise Rédiní

This figure shows the co-authorship network connecting the top 25 collaborators of Françoise Rédiní. A scholar is included among the top collaborators of Françoise Rédiní based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Françoise Rédiní. Françoise Rédiní is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience 2024 ·Pediatric Blood & Cancer ·Paul Bastard, Nathalie Cozic, Régis Brion, Nathalie Gaspar, Sophie Piperno‐Neumann, (unknown), (unknown), (unknown), Françoise Rédiní, Antonin Marchais, (unknown), (unknown), Valérie Laurence, Charlotte Rigaud, Rachid Abbas, Franck Verrecchia, Laurence Brugières, Véronique Minard‐Colin	1
2	Characterization of the Tumor Microenvironment in Jaw Osteosarcomas, towards Prognostic Markers and New Therapeutic Targets 2023 ·Cancers ·Hélios Bertin, (unknown), Jérôme Amiaud, Nathalie Van Acker, Bastien Perrot, Corinne Bouvier, Sébastien Aubert, Béatrice Marie, Fréderique Larousserie, Gonzague de Pinieux, Vincent Crenn, Françoise Rédiní, Anne Gomez‐Brouchet	5
3	Pyridazinone Derivatives Limit Osteosarcoma-Cells Growth In Vitro and In Vivo 2021 ·Cancers ·(unknown), Julien Braux, (unknown), Christine Guillaume, (unknown), (unknown), Sandra Audonnet, (unknown), Françoise Rédiní, (unknown), János Sápi, Sophie C. Gangloff, Stéphane Gérard, Frédéric Velard	4
4	Overexpression of the Ubiquitin Specific Proteases USP43, USP41, USP27x and USP6 in Osteosarcoma Cell Lines: Inhibition of Osteosarcoma Tumor Growth and Lung Metastasis Development by the USP Antagonist PR619 2021 ·Cells ·(unknown), (unknown), (unknown), Jérôme Amiaud, Mélanie Legrand, (unknown), Régis Brion, Sarah Morice, (unknown), (unknown), Bénédicte Brounais-Le Royer, François Lamoureux, Benjamin Ory, Françoise Rédiní, Franck Verrecchia	25
5	The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth 2020 ·Cancers ·Sarah Morice, (unknown), Régis Brion, (unknown), (unknown), (unknown), Bénédicte Brounais-Le Royer, Benjamin Ory, Françoise Rédiní, Franck Verrecchia	30
6	Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression 2015 ·Clinical Cancer Research ·Benjamin Ory, Marc Baud’huin, Franck Verrecchia, Bénédicte Brounais-Le Royer, Thibaut Quillard, Jérôme Amiaud, Séverine Battaglia, Dominique Heymann, Françoise Rédiní, François Lamoureux	28
7	Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma 2014 ·Clinical Cancer Research ·Audrey Lamora, Julie Talbot, Gwenola Bougras, Jérôme Amiaud, Marion Leduc, Julie Chesneau, Julien Taurelle, Verena Stresing, Marie‐Cécile Le Deley, Marie‐Françoise Heymann, Dominique Heymann, Françoise Rédiní, Franck Verrecchia	90
8	Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid 2014 ·Bone ·Frédéric Lézot, Julie Chesneau, (unknown), (unknown), Jérôme Amiaud, Yongwon Choi, Hideo Yagita∥, Beatriz Castañeda, Ariane Berdal, Christopher G. Mueller, Françoise Rédiní, Dominique Heymann	27
9	Targeting the EWSR1-FLI1 Oncogene-Induced Protein Kinase PKC-β Abolishes Ewing Sarcoma Growth 2012 ·Cancer Research ·Didier Surdez, Magdalena Benetkiewicz, Virginie Perrin, Zhi‐Yan Han, Gaëlle Pierron, Stelly Ballet, François Lamoureux, Françoise Rédiní, Anne‐Valérie Decouvelaere, Estelle Daudigeos‐Dubus, Birgit Geoerger, Gonzague de Pinieux, Olivier Delattre, Franck Tirode	44
10	Oncostatin M Is a Growth Factor for Ewing Sarcoma 2012 ·American Journal Of Pathology ·Emmanuelle David, Franck Tirode, Marc Baud’huin, Pierre Guihard, Karine Laud, Olivier Delattre, Marie‐Françoise Heymann, Dominique Heymann, Françoise Rédiní, Frédéric Blanchard	34
11	Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients 2010 ·Cancer Research ·Guillaume Odri, (unknown), Gaëlle Picarda, Séverine Battaglia, François Lamoureux, Nadège Corradini, Julie Rousseau, Franck Tirode, Karine Laud, Olivier Delattre, F. Gouin, Dominique Heymann, Françoise Rédiní	56
12	Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process 2010 ·Cancer Research ·Gatien Moriceau, Benjamin Ory, Laura Mitrofan, Chiara Riganti, Frédéric Blanchard, Régis Brion, Céline Charrier, Séverine Battaglia, Paul Pilet, Marc G. Denis, Leonard D. Shultz, Jukka Mönkkönen, Françoise Rédiní, Dominique Heymann	74
13	16: Caractérisation par imagerie TEMP, microTEP au 18F-FDG, et microscanner d’un modèle murin d’ostéosarcome orthotopique 2010 ·Bulletin du Cancer ·(unknown), F. Gouin, Nicole Moins, Dominique Heymann, Françoise Rédiní, Jean‐Michel Chezal	1
14	Oncostatin M Induces Bone Loss and Sensitizes Rat Osteosarcoma to the Antitumor Effect of Midostaurin In vivo 2008 ·Clinical Cancer Research ·Bénédicte Brounais, Céline Chipoy, Kanji Mori, Céline Charrier, Séverine Battaglia, Paul Pilet, Carl D. Richards, Dominique Heymann, Françoise Rédiní, Frédéric Blanchard	32
15	Receptor activator of nuclear factor-κB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells 2007 ·Oncology Reports ·Kanji Mori, Martine Berreur, Frédéric Blanchard, Catherine Chevalier, Isabelle Guisle‐Marsollier, Martial Masson, Françoise Rédiní, Dominique Heymann	65
16	Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53 2007 ·Oncogene ·Céline Chipoy, Bénédicte Brounais, Valérie Trichet, Séverine Battaglia, Martine Berreur, Lisa Oliver, Philippe Juin, Françoise Rédiní, Dominique Heymann, Frédéric Blanchard	43
17	Receptor Activator of Nuclear Factor κB Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis 2003 ·American Journal Of Pathology ·Eva Grimaud, (unknown), Séverine Couillaud, Patrick Coipeau, Philippe Moreau, Norbert Passuti, F. Gouin, Françoise Rédiní, Dominique Heymann	228
18	Osteoprotegerin: a new therapeutic agent for the treatment of bone disease 2001 ·Drug Discovery Today ·Eva Grimaud, Françoise Rédiní, Dominique Heymann	14
19	Effects of glycosaminoglycans and extracellular matrix components on metastatic rat rhabdomyosarcoma tumor and myoblast cell proliferation 1990 ·Clinical & Experimental Metastasis ·Françoise Rédiní, E. Móczár, M F Poupon	8
20	Cell surface glycosaminoglycans of rat rhabdomyosarcoma lines with different metastatic potentials and of non-malignant rat myoblasts 1986 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Françoise Rédiní, E. Móczár, (unknown)	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact